Maxiflo 250 Inhaler is a combination respiratory medication containing Formoterol (6 mcg) and Fluticasone Propionate (250 mcg) per actuation, indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Formoterol, a long-acting beta2-adrenergic agonist (LABA), provides bronchodilation by relaxing airway smooth muscle, resulting in improved airflow and symptom relief. Fluticasone Propionate, a potent inhaled corticosteroid, exerts anti-inflammatory effects by inhibiting multiple inflammatory cells and mediators, thereby reducing airway inflammation and hyperresponsiveness. Maxiflo 250 Inhaler is designed for twice-daily administration to achieve sustained control of respiratory symptoms, reduce exacerbation frequency, and improve lung function. It is essential for patients to use the inhaler regularly, even in the absence of symptoms, to maintain optimal disease control. Common adverse effects may include oral candidiasis, hoarseness, and throat irritation; thus, rinsing the mouth after use is recommended to minimize these risks. Maxiflo 250 should be used with caution in patients with cardiovascular disorders, and abrupt discontinuation should be avoided to prevent exacerbation of symptoms. This inhaler is contraindicated in patients with hypersensitivity to any of its components. Proper inhaler technique and adherence to prescribed dosing are critical for therapeutic efficacy.